Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Oncolytics Biotech Inc T.ONC

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.
Price: $0.37 Volume: 21,631
Change: +$0.01 % Change: +2.78%
Day High/Low: 0.38/0.37 52 Week High/Low: 1.74/0.335
Last Traded: February 10, 2016 08:55 Transaction Volume: 2000
Open: 0.375 Previous Close: 0.36
Bid: 0.37 Ask: 0.38
Bid Size: 500 Ask Size: 2000
Market Cap: 43.7m Shares Out: 118.2m
PE Ratio: N/A Dividend Yield: N/A


Canadian Biotech comes back to life: A buyer's guide

Everything you could ever want to know about biotech, biomed and bio investments up north.

Tony Pullen   January 21, 2014
0 stars

Latest Bullboard Posts

  • wow

    0 stars

    sure glade I invested in this company

    1.5 stars

  • RE:BT on Canada AM

    0 stars

    Missed this interview when it es broadcast, good to see this clip ... finally some news that might show some light at the end of the...

    2 stars

  • BT on Canada AM

    0 stars

    2.5 stars

  • Registration Trial

    0 stars

    Anyone have an idea when we can expect the results of the bladder registration trial? Perhaps in 2016! They appear to be going into this...

    2 stars

  • Merck on a buying spree

    0 stars

    According to their recent news release they will be looking at acquisitions in 2016, 2015 was a busy year and maybe all of the cream of...

    2.5 stars